Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/PARG_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PARG_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PARG_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PARG_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PARG_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000609127 | Thyroid | HT | generation of precursor metabolites and energy | 73/1272 | 490/18723 | 1.63e-10 | 2.21e-08 | 73 |
GO:006053718 | Thyroid | HT | muscle tissue development | 62/1272 | 403/18723 | 1.10e-09 | 1.20e-07 | 62 |
GO:006219730 | Thyroid | HT | cellular response to chemical stress | 54/1272 | 337/18723 | 3.07e-09 | 2.89e-07 | 54 |
GO:000989528 | Thyroid | HT | negative regulation of catabolic process | 50/1272 | 320/18723 | 2.72e-08 | 2.02e-06 | 50 |
GO:003459929 | Thyroid | HT | cellular response to oxidative stress | 46/1272 | 288/18723 | 4.97e-08 | 3.15e-06 | 46 |
GO:007048227 | Thyroid | HT | response to oxygen levels | 50/1272 | 347/18723 | 3.61e-07 | 1.65e-05 | 50 |
GO:003629327 | Thyroid | HT | response to decreased oxygen levels | 46/1272 | 322/18723 | 1.34e-06 | 5.14e-05 | 46 |
GO:000166627 | Thyroid | HT | response to hypoxia | 44/1272 | 307/18723 | 2.07e-06 | 7.53e-05 | 44 |
GO:001003830 | Thyroid | HT | response to metal ion | 50/1272 | 373/18723 | 3.12e-06 | 1.08e-04 | 50 |
GO:000926623 | Thyroid | HT | response to temperature stimulus | 30/1272 | 178/18723 | 3.37e-06 | 1.13e-04 | 30 |
GO:000762324 | Thyroid | HT | circadian rhythm | 33/1272 | 210/18723 | 5.38e-06 | 1.66e-04 | 33 |
GO:000756828 | Thyroid | HT | aging | 46/1272 | 339/18723 | 5.52e-06 | 1.68e-04 | 46 |
GO:00970673 | Thyroid | HT | cellular response to thyroid hormone stimulus | 8/1272 | 17/18723 | 6.20e-06 | 1.86e-04 | 8 |
GO:003428428 | Thyroid | HT | response to monosaccharide | 34/1272 | 225/18723 | 9.32e-06 | 2.59e-04 | 34 |
GO:003292218 | Thyroid | HT | circadian regulation of gene expression | 16/1272 | 68/18723 | 9.48e-06 | 2.62e-04 | 16 |
GO:007124119 | Thyroid | HT | cellular response to inorganic substance | 34/1272 | 226/18723 | 1.03e-05 | 2.79e-04 | 34 |
GO:004851120 | Thyroid | HT | rhythmic process | 41/1272 | 298/18723 | 1.26e-05 | 3.27e-04 | 41 |
GO:000193327 | Thyroid | HT | negative regulation of protein phosphorylation | 45/1272 | 342/18723 | 1.54e-05 | 3.80e-04 | 45 |
GO:004232627 | Thyroid | HT | negative regulation of phosphorylation | 49/1272 | 385/18723 | 1.62e-05 | 3.95e-04 | 49 |
GO:004593629 | Thyroid | HT | negative regulation of phosphate metabolic process | 54/1272 | 441/18723 | 1.86e-05 | 4.39e-04 | 54 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARG | SNV | Missense_Mutation | novel | c.2006N>T | p.Ser669Leu | p.S669L | Q86W56 | protein_coding | deleterious(0.02) | probably_damaging(0.989) | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PARG | insertion | Frame_Shift_Ins | novel | c.1451_1452insCT | p.Arg485PhefsTer3 | p.R485Ffs*3 | Q86W56 | protein_coding | | | TCGA-S3-AA11-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | CR |
PARG | SNV | Missense_Mutation | rs4614387 | c.1453N>T | p.Arg485Trp | p.R485W | Q86W56 | protein_coding | deleterious(0) | benign(0.072) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PARG | SNV | Missense_Mutation | novel | c.517N>G | p.Gln173Glu | p.Q173E | Q86W56 | protein_coding | tolerated_low_confidence(0.16) | benign(0.001) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
PARG | SNV | Missense_Mutation | novel | c.2515N>C | p.Glu839Gln | p.E839Q | Q86W56 | protein_coding | tolerated(0.06) | benign(0.312) | TCGA-EK-A3GJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PARG | SNV | Missense_Mutation | novel | c.815G>A | p.Gly272Asp | p.G272D | Q86W56 | protein_coding | tolerated_low_confidence(0.64) | benign(0.049) | TCGA-VS-A8EB-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | PD |
PARG | SNV | Missense_Mutation | novel | c.1199C>G | p.Ser400Cys | p.S400C | Q86W56 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.628) | TCGA-VS-A8Q8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
PARG | deletion | Frame_Shift_Del | novel | c.2808delN | p.Tyr936Ter | p.Y936* | Q86W56 | protein_coding | | | TCGA-C5-A7X3-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
PARG | SNV | Missense_Mutation | novel | c.2173N>G | p.Thr725Ala | p.T725A | Q86W56 | protein_coding | deleterious(0.02) | benign(0.359) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PARG | SNV | Missense_Mutation | novel | c.1865C>G | p.Ser622Cys | p.S622C | Q86W56 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-AA-3662-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | capecitabine | PR |